Global Critical Care Antiarrhythmic Drugs Market to Reach USD 1321.32 Million by 2027, Aided by the Regulatory Backing to Novel Drug Formulations

An increase in the prevalence of cardiovascular disorders in various parts of the world, along with an increase in the number of geriatric populations suffering from chronic diseases, are likely to enhance the antiarrhythmic drugs market over the forecast period. The COVID-19 pandemic has emphasised the need of maintaining heart health, as people with heart-related comorbidities are more likely to contract the coronavirus. As a result of the coronavirus, critical care anti-arrhythmogenic medications have become more widely used around the world. Rising FDA approvals of new antiarrhythmic drugs for treating atrial arrhythmias and a significant number of antiarrhythmic agents under development for several indications are projected to create new market opportunities.

Clinical trials and the development of novel drugs are being heavily pursued by a number of government-funded organisations, academic institutions, and private businesses, which are contributing to the market's growth. For example, ANI Pharmaceuticals (NASDAQ: ANIP) launched Mexiletine Hydrochloride Capsules USP in June 2020, marking the company's sixth generic pharmaceutical launch of the year. The capsules are recommended for the treatment of life-threatening ventricular arrhythmias.

Market Analysis by Drug Class, End-Use, and Regions:

• Based on drug class, the market is divided into bovine, human, and recombinant, among others.
• On the basis of end-use, the market is divided into hospitals and diagnostics, among others.
• The regional markets for critical care antiarrhythmic drugs include North America, Europe, Asia Pacific, Latin America, and the Middle East, and Africa.

Key Findings of the Report:

• Increasing research and development activities is estimated to boost the market growth.
• Increased disease awareness is further augmenting the growth of the market.
• The advanced health care infrastructure is further propelling the growth of the market.
• Government intervention in curbing the number of deaths is further aiding in market growth.

Key Offerings of the Report:

• The EMR report gives an overview of the global critical care antiarrhythmic drugs market for the periods (2017-2021) and (2022-2027).
• The report also offers the historical (2017-2021) and forecasted (2022-2027) markets for drug class, end-use, and major regions of critical care antiarrhythmic drugs.
• The report analyses the market dynamics, covering the key demand and price indicators in the market, along with providing an assessment of the SWOT and Porter’s Five Forces models.

The major players in the global critical care antiarrhythmic drugs industry are Pfizer, GlaxoSmithKline plc, Sanofi, Mylan N.V., Upsher-Smith Laboratories LLC, Novartis AG, and Mayne Pharma, among others. The comprehensive report by EMR looks into the market share, capacity, and latest developments like mergers and acquisitions, plant turnarounds, and capacity expansions of the major players.

About Us

Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.

EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium-sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.

Contact Us:

Expert Market Research
Website: www.expertmarketresearch.com
Email: sales@expertmarketresearch.com
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-579

*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.